tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Medtecs Updates on Resilient Medical Liquidation Proceedings

Story Highlights
  • A creditors’ meeting for Resilient Medical was not held due to lack of quorum.
  • The liquidation of Resilient Medical is not expected to impact Medtecs’ financial performance.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Medtecs Updates on Resilient Medical Liquidation Proceedings

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Medtecs International Corporation Ltd. ( (SG:546) ) has provided an update.

Medtecs International Corporation Ltd. announced that a creditors’ meeting for its subsidiary, Resilient Medical, was not held due to the absence of a quorum. The Liquidator will proceed with the necessary legal steps to conclude the liquidation process. The company stated that the winding-up of Resilient Medical will not materially impact its financial performance for the year ending December 31, 2025, as the outstanding receivables are approximately equivalent to the net tangible assets of RMKH SG and its subsidiary.

More about Medtecs International Corporation Ltd.

Medtecs International Corporation Ltd. is a company incorporated in Bermuda, operating within the healthcare industry. It focuses on providing medical supplies and services, with a market focus that includes the management of subsidiaries such as Resilient Medical.

Average Trading Volume: 3,079,532

Technical Sentiment Signal: Sell

Current Market Cap: S$71.03M

For detailed information about 546 stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1